Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies
- PMID: 38863622
- PMCID: PMC11165151
- DOI: 10.3389/fonc.2024.1405491
Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies
Abstract
Triple-negative breast cancer (TNBC) poses significant challenges in oncology due to its aggressive nature, limited treatment options, and poorer prognosis compared to other breast cancer subtypes. This comprehensive review examines the therapeutic and diagnostic landscape of TNBC, highlighting current strategies, emerging therapies, and future directions. Targeted therapies, including PARP inhibitors, immune checkpoint inhibitors, and EGFR inhibitors, hold promise for personalized treatment approaches. Challenges in identifying novel targets, exploring combination therapies, and developing predictive biomarkers must be addressed to optimize targeted therapy in TNBC. Immunotherapy represents a transformative approach in TNBC treatment, yet challenges in biomarker identification, combination strategies, and overcoming resistance persist. Precision medicine approaches offer opportunities for tailored treatment based on tumor biology, but integration of multi-omics data and clinical implementation present challenges requiring innovative solutions. Despite these challenges, ongoing research efforts and collaborative initiatives offer hope for improving outcomes and advancing treatment strategies in TNBC. By addressing the complexities of TNBC biology and developing effective therapeutic approaches, personalized treatments can be realized, ultimately enhancing the lives of TNBC patients. Continued research, clinical trials, and interdisciplinary collaborations are essential for realizing this vision and making meaningful progress in TNBC management.
Keywords: diagnostic challenges; immunotherapy; precision medicine; targeted therapies; therapeutic challenges; triple-negative breast cancer.
Copyright © 2024 Xiong, Wu and Yu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Narrative review on the role of immunotherapy in early triple negative breast cancer: unveiling opportunities and overcoming challenges.Transl Breast Cancer Res. 2023 Apr 30;4:16. doi: 10.21037/tbcr-23-17. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751461 Free PMC article. Review.
-
Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges.Vaccines (Basel). 2025 Mar 24;13(4):344. doi: 10.3390/vaccines13040344. Vaccines (Basel). 2025. PMID: 40333213 Free PMC article. Review.
-
Multi-omic analysis of dysregulated pathways in triple negative breast cancer.Asia Pac J Clin Oncol. 2024 Jun 20. doi: 10.1111/ajco.14095. Online ahead of print. Asia Pac J Clin Oncol. 2024. PMID: 38899578 Review.
-
Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.Front Mol Biosci. 2022 Aug 19;9:903065. doi: 10.3389/fmolb.2022.903065. eCollection 2022. Front Mol Biosci. 2022. PMID: 36060249 Free PMC article. Review.
-
DNA damage response and neoantigens: A favorable target for triple-negative breast cancer immunotherapy and vaccine development.Int Rev Cell Mol Biol. 2024;389:104-152. doi: 10.1016/bs.ircmb.2024.05.001. Epub 2024 Jun 4. Int Rev Cell Mol Biol. 2024. PMID: 39396845 Review.
Cited by
-
Targeting DNA damage repair mechanism by using RAD50-silencing siRNA nanoparticles to enhance radiotherapy in triple negative breast cancer.Mater Today Bio. 2024 Aug 16;28:101206. doi: 10.1016/j.mtbio.2024.101206. eCollection 2024 Oct. Mater Today Bio. 2024. PMID: 39221201 Free PMC article.
-
Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer.J Pers Med. 2024 Jul 4;14(7):723. doi: 10.3390/jpm14070723. J Pers Med. 2024. PMID: 39063977 Free PMC article. Review.
-
Evaluation of CircHIPK3 biomarker potential in breast cancer.Pract Lab Med. 2025 Mar 20;45:e00470. doi: 10.1016/j.plabm.2025.e00470. eCollection 2025 Jul. Pract Lab Med. 2025. PMID: 40226123 Free PMC article.
-
RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review).Int J Oncol. 2025 Aug;67(2):65. doi: 10.3892/ijo.2025.5771. Epub 2025 Jul 4. Int J Oncol. 2025. PMID: 40613200 Free PMC article. Review.
-
Predicting Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer Using Pre-Treatment Histopathologic Images.Cancers (Basel). 2025 Jul 22;17(15):2423. doi: 10.3390/cancers17152423. Cancers (Basel). 2025. PMID: 40805125 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous